BTIG Research Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its target price decreased by equities researchers at BTIG Research from $145.00 to $140.00 in a note issued to investors on Tuesday,MarketScreener reports. The firm currently has a “buy” rating on the healthcare product maker’s stock. BTIG Research’s price objective would indicate a potential upside of 24.46% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. Evercore dropped their price target on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Daiwa Securities Group dropped their target price on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Finally, William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Trading Up 0.2%

Shares of ABT stock traded up $0.23 during trading hours on Tuesday, reaching $112.49. The company’s stock had a trading volume of 300,660 shares, compared to its average volume of 11,215,390. The firm’s fifty day simple moving average is $119.12 and its 200 day simple moving average is $126.18. Abbott Laboratories has a one year low of $105.27 and a one year high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $195.60 billion, a P/E ratio of 30.13, a P/E/G ratio of 1.79 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Wednesday, February 4th. The shares were acquired at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.46% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ABT. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories in the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories in the fourth quarter valued at $26,000. Abound Financial LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $27,000. Institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.